Characterization of 111In and 177Lu-labeled antibodies binding to CD44v6 using a novel automated radioimmunoassay

Journal of Molecular Recognition

Volumn 21, Issue 3, 2008, Pages 179-183

  Nestor, Marika ^a,b   Andersson, Karl ^b,c   Lundqvist, Hans ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c Ridgeview Instruments AB   (Sweden)

Author keywords

Affinity; Cancer; Kinetics; Medical imaging; Targeted therapeutics

Indexed keywords

CD44V6 ANTIGEN; HERMES ANTIGEN; INDIUM; LUTETIUM; MONOCLONAL ANTIBODY;

ARTICLE; AUTOMATION; HUMAN; IMMUNOLOGY; ISOTOPE LABELING; METABOLISM; METHODOLOGY; RADIOIMMUNOASSAY; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD44; AUTOMATION; CELL LINE, TUMOR; HUMANS; INDIUM RADIOISOTOPES; ISOTOPE LABELING; LUTETIUM; RADIOIMMUNOASSAY;

EID: 44949139561     PISSN: 09523499     EISSN: 10991352     Source Type: Journal    
DOI: 10.1002/jmr.883     Document Type: Article

References (24)

1. Adams DJ, Wahl ML, Flowers JL, Sen B, Colvin M, Dewhirst MW, Manikumar G, Wani MC. 2006. Camptothecin analogs with enhanced activity against human breast cancer cells. II. Impact of the tumor pH gradient. Cancer Chemother. Pharmacol. 57: 145-154.
2. Bjorke H, Andersson K. 2006a. Automated, high-resolution cellular retention and uptake studies in vitro. Appl. Radiat. Isot. 64: 901-905.
3. Bjorke H, Andersson K. 2006b. Measuring the affinity of a radioligand with its receptor using a rotating cell dish with in situ reference area. Appl. Radiat. Isot. 64: 32-37.
4. Boswell CA, Brechbiel MW. 2007. Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nucl. Med. Biol. 34: 757-778.
5. Brakenhoff RH, van Gog FB, Looney JE, van Walsum M, Snow GB, van Dongen GA. 1995. Construction and characterization of the chimeric monoclonal antibody E48 for therapy of head and neck cancer. Cancer Immunol. Immunother. 40: 191-200.
6. Braun AH, Stark K, Dirsch O, Hilger RA, Seeber S, Vanhoefer U. 2005. The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan. Anticancer Drugs 16: 1099-1108.
7. Carlsson J, Forssell-Aronsson E, Hietala SO, Stigbrand T, Tennvall J. 2003. Tumour therapy with radionuclides: assessment of progress and problems. Radiother. Oncol. 66: 107-117.
8. Carlsson J, Forssell-Aronsson E, Glimelius B, Mattsson S. 2002. Therapy with radiopharmaceuticals. Acta Oncol. 41: 623-628.
9. Cheng J, Ekberg T, Engstrom M, Nestor M, Jensen HJ, Tolmachev V, et al., 2007. Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma. Laryngoscope 117: 1013-1018.
10. Dearling JL, Pedley RB. 2007. Technological advances in radioimmunotherapy. Clin. Oncol. (R. Coll. Radiol.) 19: 457-469.
11. Fortin MA, Nestor M, Salnikov AV, Heldin NE, Rubin K, Lundqvist H. 2007. Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies. Eur. J. Nucl. Med. Mol. Imaging. 2007 Sep; 34(9): 1376-87.
12. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. 1995. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1: 1311-1318.
13. Lub-de Hooge MN, Kosterink JG, Perik PJ, Nijnuis H, Tran L, Bart J, Suurmeijer AJ, de Jong S, Jager PL, de Vries EG. 2004. Preclinical characterisation of 111In-DTPA-trastuzumab. Br. J. Pharmacol. 143: 99-106.
14. Mendelsohn J, Baselga J. 2003. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 21: 2787-2799.
15. Miao Y, Hoffman TJ, Quinn TP. 2005. Tumor-targeting properties of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues in a murine melanoma model. Nucl. Med. Biol. 32: 485-493.
16. Nestor M, Persson M, van Dongen GA, Jensen HJ, Lundqvist H, Anniko M, Tolmachev V. 2005. In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma. Eur. J. Nucl. Med. Mol. Imaging 32: 1296-1304.
17. Nordberg E, Steffen AC, Persson M, Sundberg AL, Carlsson J, Glimelius B. 2005. Cellular uptake of radioiodine delivered by trastuzumab can be modified by the addition of epidermal growth factor. Eur. J. Nucl. Med. Mol. Imaging 32: 771-777.
18. Oyen WJ, Bodei L, Giammarile F, Maecke HR, Tennvall J, Luster M, Brans B. 2007. Targeted therapy in nuclear medicine - current status and future prospects. Ann. Oncol. 18: 1782-1792.
19. Persson M, Tolmachev V, Andersson K, Gedda L, Sandstrom M, Carlsson J. 2005. [(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells. Eur. J. Nucl. Med. Mol. Imaging. 2005 Dec; 32(12): 1457-62.
20. Sakamoto J, Kojima H, Kato J, Hamashima H, Suzuki H. 2000. Organ-specific expression of the intestinal epithelium-related antigen A33, a cell surface target for antibody-based imaging and treatment in gastrointestinal cancer. Cancer Chemother. Pharmacol. 46 (Suppl): S27-32.
21. Schrijvers AH, Quak JJ, Uyterlinde AM, van Walsum M, Meijer CJ, Snow GB, van Dongen GA. 1993. MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck. Cancer Res. 53: 4383-4390.
22. Scott-Robson S, Capala J, Carlsson J, Malmborg P, Lundqvist H. 1991. Distribution and stability in the rat of a 76Br/125I-labelled polypeptide, epidermal growth factor. Int. J. Rad. Appl. Instrum. B 18: 241-246.
23. Tolmachev V, Orlova A, Wei Q, Bruskin A, Carlsson J, Gedda L. 2004. Comparative biodistribution of potential anti-glioblastoma conjugates [111In]DTPA-hEGF and [111In]Bz-DTPA-hEGF in normal mice. Cancer Biother. Radiopharm. 19: 491-501.
24. Wei Q, Kullberg EB, Gedda L. 2003. Trastuzumab-conjugated boron-containing liposomes for tumor-cell targeting; development and cellular studies. Int. J. Oncol. 23: 1159-1165.